Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8;   Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8;   Thyroid Gland Squamous Cell Carcinoma;   Unresectable Thyroid Gland Carcinoma
Interventions:   Drug: Lenvatinib;   Biological: Pembrolizumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments